[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100469492":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":31,"centralContacts":35,"locations":44,"responsibleParty":63,"collaborators":65,"id":71,"slug":72,"hasResults":73,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":77,"eligibilityCriteria":78,"healthyVolunteers":73,"sex":79,"minAge":80,"maxAge":81,"enrollmentInfo":82,"targetDuration":26,"studyType":85,"phases":86,"briefSummary":88,"conditions":89,"keywords":93,"overallStatus":47,"whyStopped":26,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":108},{"fullName":5,"class":6},"University Hospital, Bordeaux","OTHER",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"Drug resistant epilepsy with GAD","EXPERIMENTAL","Patients suffering from drug-resistant epilepsy and generalized anxiety disorders (GAD),explored by intracranial EEG (seteroelectroencephalography - SEEG) in Hospital",[13,14],"Behavioral: Anxiety-induced task","Behavioral: Neuropsychiatric assessment",{"label":16,"type":17,"description":18,"interventionNames":19},"Drug resistant epilepsy without GAD","ACTIVE_COMPARATOR","Patients suffering from drug-resistant epilepsy without generalized anxiety disorders (GAD),explored by intracranial EEG (seteroelectroencephalography - SEEG) in Hospital",[13,14],[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"BEHAVIORAL","Anxiety-induced task","Subjects will be asked to describe their most anxious thoughts and write each of them in a detailed scenario. The scenarios will be based on the answers to the Worry and Anxiety Questionnaire, in order to validate the procedure by a standardized examination. During the task, the scenarios will be successively presented to the subjects, on a digital computer medium in written and oral format. Subjects will be asked to actively focus on these negative thoughts with maximum concern, without seeking to control their emotions.",[9,16],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"Neuropsychiatric assessment","Screening for depression and anxiety",[9,16],[32],{"name":33,"affiliation":5,"role":34},"Jérôme Aupy, Dr","PRINCIPAL_INVESTIGATOR",[36,40],{"name":33,"role":37,"phone":38,"phoneExt":26,"email":39},"CONTACT","05 56 79 56 79","jerome.aupy@chu-bordeaux.fr",{"name":41,"role":37,"phone":42,"phoneExt":26,"email":43},"Thomas Bienvenu, Dr","05 56 56 17 98","thomas.bienvenu@u-bordeaux.fr",[45],{"facility":46,"status":47,"city":48,"state":26,"zip":49,"country":50,"countryCode":51,"cosmosGeoPoint":52,"geoPoint":57,"contacts":58},"CHU de Bordeaux","RECRUITING","Bordeaux","33076","France","FR",{"type":53,"coordinates":54},"Point",[55,56],-0.58046,44.84124,{"lat":56,"lon":55},[59,61],{"name":60,"role":37,"phone":38,"phoneExt":26,"email":39},"Jérôme AUPY, Dr",{"name":62,"role":37,"phone":42,"phoneExt":26,"email":43},"Thomas BIENVENU",{"type":64,"investigatorFullName":26,"investigatorTitle":26,"investigatorAffiliation":26,"oldNameTitle":26,"oldOrganization":26},"SPONSOR",[66,68],{"name":67,"class":6},"Centre National de la Recherche Scientifique, France",{"name":69,"class":70},"Institut National de la Santé Et de la Recherche Médicale, France","OTHER_GOV","100469492","electroclinical-correlation-of-anxiety-100469492",false,"NCT05393518","Electroclinical Correlation of Anxiety","Electroclinical Correlation of Anxiety, Evidences From Intracerebral Recordings","IRAnxNet","Inclusion Criteria:\n\n* Man or woman\n* Aged 18 to 65;\n* With drug-resistant epilepsy\n* Benefiting from a phase II pre-surgical assessment with intracerebral electrophysiological exploration by stereo-EEG\n* Meeting the DSM-5 diagnostic criteria for generalized anxiety disorder (\"pathological\" population) or not meeting the DSM-5 diagnostic criteria for generalized anxiety disorder (\"control\" population)\n* WAIS IV full scale IQ \\> 75 or IAG \\> 81\n* Affiliate or beneficiary of a social security scheme\n* Giving free, informed consent in writing and signed by the participant and the investigator\n\nExclusion Criteria:\n\n* Being unable to give personal consent\n* Be subject to a measure of legal protection (curatorship, guardianship) or placed under judicial protection;\n* Suffer from a chronic delusional disorder (eg: schizophrenia);\n* Have a moderate or high risk of suicide assessed using the corresponding section of the structured psychiatric interview called \"Mini International Neuropsychiatric Interview\" (M.I.N.I. 7.0) or a score \\> 2 on item 10 of the MADRS, assessing suicidal risk;\n* Being pregnant or breastfeeding\n* Have severe and \u002F or decompensated somatic illness other than drug-resistant epilepsy","ALL","18 Years","65 Years",{"count":83,"type":84},30,"ESTIMATED","INTERVENTIONAL",[87],"NA","Anxiety disorders have the highest prevalence among mental disorders and cause considerable individual and financial costs. Current treatments do not relieve mental suffering of many patients. Understanding neurobiological mechanisms involved in pathological anxiety is a major scientific challenge.",[90,91,92],"Anxiety Disorder","Generalized Anxiety Disorder","Drug Resistant Epilepsy",[94,91,95,96,97,98],"Focal epilepsy","Intracranial recordings","Stereoenectroencephalography","Coherence","Networks","2025-07-22",{"date":101,"type":102},"2025-07-25","ACTUAL",{"date":104,"type":102},"2022-10-11",{"date":106,"type":84},"2026-10-11",{"name":5,"class":6},1]